Skip to main content
Erschienen in: European Radiology 12/2022

16.06.2022 | Ultrasound

Perfluorobutane-enhanced ultrasonography with a Kupffer phase: improved diagnostic sensitivity for hepatocellular carcinoma

verfasst von: Jeong Ah Hwang, Woo Kyoung Jeong, Hyo-Jin Kang, Eun Sun Lee, Hyun Jeong Park, Jeong Min Lee

Erschienen in: European Radiology | Ausgabe 12/2022

Einloggen, um Zugang zu erhalten

Abstract

Objectives

To evaluate the diagnostic accuracy of perfluorobutane contrast-enhanced ultrasonography (CEUS) for hepatocellular carcinoma (HCC) and to explore how accuracy can be improved compared to conventional diagnostic criteria in at-risk patients.

Methods

A total of 123 hepatic nodules (≥ 1 cm) from 123 at-risk patients who underwent perfluorobutane CEUS between 2013 and 2020 at three institutions were retrospectively analyzed. Ninety-three percent of subjects had pathological results, except benign lesions stable in follow-up images. We evaluated presence of arterial phase hyperenhancement (APHE), washout time and degree, and Kupffer phase (KP) defects. KP defects are defined as hypoenhancing lesions relative to the liver in KP. HCC was diagnosed in two ways: (1) Liver Imaging Reporting and Data System (LI-RADS) criteria defined as APHE and late (≥ 60 s)/mild washout, and (2) APHE and Kupffer (AK) criteria defined as APHE and KP defect. We explored grayscale features that cause misdiagnosis of HCC and reflected in the adjustment. Diagnostic performance was compared using McNemar’s test.

Results

There were 77 HCCs, 15 non-HCC malignancies, and 31 benign lesions. An ill-defined margin without hypoechoic halo on grayscale applied as a finding that did not suggest HCC. Regarding diagnosis of HCC, sensitivity of AK criteria (83.1%; 95% confidence interval [CI]: 72.9–90.7%) was higher than that of LI-RADS criteria (75.3%; 95% CI: 64.2–84.4%; p = 0.041). Specificity was 91.3% (95% CI: 79.2–97.6%) in both groups.

Conclusion

On perfluorobutane CEUS, diagnostic criteria for HCC using KP defect with adjustment by grayscale findings had higher diagnostic performance than conventional criteria without losing specificity.

Key Points

• Applying Kupffer phase defect instead of late/mild washout and adjusting with grayscale findings can improve the diagnostic performance of perfluorobutane-enhanced US for HCC.
• Adjustment with ill-defined margins without a hypoechoic halo for features unlikely to be HCC decreases false positives for HCC diagnosis using the perfluorobutane-enhanced US.
• After adjustment with grayscale findings, the sensitivity and accuracy of the APHE and Kupffer criteria were higher than those of the LI-RADS criteria; specificity was 91.3% for both.
Anhänge
Nur mit Berechtigung zugänglich
Literatur
1.
Zurück zum Zitat Yanagisawa K, Moriyasu F, Miyahara T, Yuki M, Iijima H (2007) Phagocytosis of ultrasound contrast agent microbubbles by Kupffer cells. Ultrasound Med Biol 33:318–325 CrossRefPubMed Yanagisawa K, Moriyasu F, Miyahara T, Yuki M, Iijima H (2007) Phagocytosis of ultrasound contrast agent microbubbles by Kupffer cells. Ultrasound Med Biol 33:318–325 CrossRefPubMed
2.
Zurück zum Zitat Maruyama H, Sekimoto T, Yokosuka O (2016) Role of contrast-enhanced ultrasonography with Sonazoid for hepatocellular carcinoma: evidence from a 10-year experience. J Gastroenterol 51:421–433 CrossRefPubMed Maruyama H, Sekimoto T, Yokosuka O (2016) Role of contrast-enhanced ultrasonography with Sonazoid for hepatocellular carcinoma: evidence from a 10-year experience. J Gastroenterol 51:421–433 CrossRefPubMed
3.
Zurück zum Zitat Jo PC, Jang HJ, Burns PN, Burak KW, Kim TK, Wilson SR (2017) Integration of contrast-enhanced US into a multimodality approach to imaging of nodules in a cirrhotic liver: how i do it. Radiology 282:317–331 CrossRefPubMed Jo PC, Jang HJ, Burns PN, Burak KW, Kim TK, Wilson SR (2017) Integration of contrast-enhanced US into a multimodality approach to imaging of nodules in a cirrhotic liver: how i do it. Radiology 282:317–331 CrossRefPubMed
4.
Zurück zum Zitat Shunichi S, Hiroko I, Fuminori M, Waki H (2009) Definition of contrast enhancement phases of the liver using a perfluoro-based microbubble agent, perflubutane microbubbles. Ultrasound Med Biol 35:1819–1827 CrossRefPubMed Shunichi S, Hiroko I, Fuminori M, Waki H (2009) Definition of contrast enhancement phases of the liver using a perfluoro-based microbubble agent, perflubutane microbubbles. Ultrasound Med Biol 35:1819–1827 CrossRefPubMed
6.
Zurück zum Zitat Zhai HY, Liang P, Yu J et al (2019) Comparison of Sonazoid and SonoVue in the diagnosis of focal liver lesions: a preliminary study. J Ultrasound Med 38:2417–2425 CrossRefPubMed Zhai HY, Liang P, Yu J et al (2019) Comparison of Sonazoid and SonoVue in the diagnosis of focal liver lesions: a preliminary study. J Ultrasound Med 38:2417–2425 CrossRefPubMed
7.
Zurück zum Zitat Kang HJ, Lee JM, Yoon JH, Lee K, Kim H, Han JK (2020) Contrast-enhanced US with sulfur hexafluoride and perfluorobutane for the diagnosis of hepatocellular carcinoma in individuals with high risk. Radiology 297:108–116 CrossRefPubMed Kang HJ, Lee JM, Yoon JH, Lee K, Kim H, Han JK (2020) Contrast-enhanced US with sulfur hexafluoride and perfluorobutane for the diagnosis of hepatocellular carcinoma in individuals with high risk. Radiology 297:108–116 CrossRefPubMed
8.
Zurück zum Zitat Hwang JA, Jeong WK, Min JH, Kim YY, Heo NH, Lim HK (2021) Sonazoid-enhanced ultrasonography: comparison with CT/MRI Liver Imaging Reporting and Data System in patients with suspected hepatocellular carcinoma. Ultrasonography 40:486–498 CrossRefPubMedPubMedCentral Hwang JA, Jeong WK, Min JH, Kim YY, Heo NH, Lim HK (2021) Sonazoid-enhanced ultrasonography: comparison with CT/MRI Liver Imaging Reporting and Data System in patients with suspected hepatocellular carcinoma. Ultrasonography 40:486–498 CrossRefPubMedPubMedCentral
9.
Zurück zum Zitat Korean Liver Cancer Association (KLCA); National Cancer Center (NCC), Goyang, Korea (2019) 2018 Korean Liver Cancer Association-National Cancer Center Korea Practice Guidelines for the Management of Hepatocellular Carcinoma. Korean J Radiol 20:1042–1113 Korean Liver Cancer Association (KLCA); National Cancer Center (NCC), Goyang, Korea (2019) 2018 Korean Liver Cancer Association-National Cancer Center Korea Practice Guidelines for the Management of Hepatocellular Carcinoma. Korean J Radiol 20:1042–1113
10.
Zurück zum Zitat European Association for the Study of the Liver (2018) EASL Clinical Practice Guidelines: management of hepatocellular carcinoma. J Hepatol 69:182–236 CrossRef European Association for the Study of the Liver (2018) EASL Clinical Practice Guidelines: management of hepatocellular carcinoma. J Hepatol 69:182–236 CrossRef
11.
Zurück zum Zitat Omata M, Cheng AL, Kokudo N et al (2017) Asia-Pacific clinical practice guidelines on the management of hepatocellular carcinoma: a 2017 update. Hepatol Int 11:317–370 CrossRefPubMed Omata M, Cheng AL, Kokudo N et al (2017) Asia-Pacific clinical practice guidelines on the management of hepatocellular carcinoma: a 2017 update. Hepatol Int 11:317–370 CrossRefPubMed
12.
Zurück zum Zitat Kudo M (2011) Diagnostic imaging of hepatocellular carcinoma: recent progress. Oncology 81(Suppl 1):73–85 CrossRefPubMed Kudo M (2011) Diagnostic imaging of hepatocellular carcinoma: recent progress. Oncology 81(Suppl 1):73–85 CrossRefPubMed
13.
Zurück zum Zitat Sugimoto K, Kakegawa T, Takahashi H et al (2020) Usefulness of modified CEUS LI-RADS for the diagnosis of hepatocellular carcinoma using Sonazoid. Diagnostics (Basel) 10:828 CrossRefPubMed Sugimoto K, Kakegawa T, Takahashi H et al (2020) Usefulness of modified CEUS LI-RADS for the diagnosis of hepatocellular carcinoma using Sonazoid. Diagnostics (Basel) 10:828 CrossRefPubMed
15.
Zurück zum Zitat Lee JY, Minami Y, Choi BI et al (2020) The AFSUMB consensus statements and recommendations for the clinical practice of contrast-enhanced ultrasound using Sonazoid. Ultrasonography 39:191–220 CrossRefPubMedPubMedCentral Lee JY, Minami Y, Choi BI et al (2020) The AFSUMB consensus statements and recommendations for the clinical practice of contrast-enhanced ultrasound using Sonazoid. Ultrasonography 39:191–220 CrossRefPubMedPubMedCentral
16.
Zurück zum Zitat Kim TK, Noh SY, Wilson SR et al (2017) Contrast-enhanced ultrasound (CEUS) liver imaging reporting and data system (LI-RADS) 2017 - a review of important differences compared to the CT/MRI system. Clin Mol Hepatol 23:280–289 CrossRefPubMedPubMedCentral Kim TK, Noh SY, Wilson SR et al (2017) Contrast-enhanced ultrasound (CEUS) liver imaging reporting and data system (LI-RADS) 2017 - a review of important differences compared to the CT/MRI system. Clin Mol Hepatol 23:280–289 CrossRefPubMedPubMedCentral
17.
Zurück zum Zitat Hatanaka K, Kudo M, Minami Y et al (2008) Differential diagnosis of hepatic tumors: value of contrast-enhanced harmonic sonography using the newly developed contrast agent, Sonazoid. Intervirology 51(Suppl 1):61–69 CrossRefPubMed Hatanaka K, Kudo M, Minami Y et al (2008) Differential diagnosis of hepatic tumors: value of contrast-enhanced harmonic sonography using the newly developed contrast agent, Sonazoid. Intervirology 51(Suppl 1):61–69 CrossRefPubMed
18.
Zurück zum Zitat Ichikawa T, Saito K, Yoshioka N et al (2010) Detection and characterization of focal liver lesions: a Japanese phase III, multicenter comparison between gadoxetic acid disodium-enhanced magnetic resonance imaging and contrast-enhanced computed tomography predominantly in patients with hepatocellular carcinoma and chronic liver disease. Invest Radiol 45:133–141 CrossRefPubMed Ichikawa T, Saito K, Yoshioka N et al (2010) Detection and characterization of focal liver lesions: a Japanese phase III, multicenter comparison between gadoxetic acid disodium-enhanced magnetic resonance imaging and contrast-enhanced computed tomography predominantly in patients with hepatocellular carcinoma and chronic liver disease. Invest Radiol 45:133–141 CrossRefPubMed
19.
Zurück zum Zitat Mita K, Kim SR, Kudo M et al (2010) Diagnostic sensitivity of imaging modalities for hepatocellular carcinoma smaller than 2 cm. World J Gastroenterol 16:4187–4192 CrossRefPubMedPubMedCentral Mita K, Kim SR, Kudo M et al (2010) Diagnostic sensitivity of imaging modalities for hepatocellular carcinoma smaller than 2 cm. World J Gastroenterol 16:4187–4192 CrossRefPubMedPubMedCentral
20.
Zurück zum Zitat Choi BI, Takayasu K, Han MC (1993) Small hepatocellular carcinomas and associated nodular lesions of the liver: pathology, pathogenesis, and imaging findings. AJR Am J Roentgenol 160:1177–1187 CrossRefPubMed Choi BI, Takayasu K, Han MC (1993) Small hepatocellular carcinomas and associated nodular lesions of the liver: pathology, pathogenesis, and imaging findings. AJR Am J Roentgenol 160:1177–1187 CrossRefPubMed
21.
Zurück zum Zitat Wernecke K, Henke L, Vassallo P et al (1992) Pathologic explanation for hypoechoic halo seen on sonograms of malignant liver tumors: an in vitro correlative study. AJR Am J Roentgenol 159:1011–1016 CrossRefPubMed Wernecke K, Henke L, Vassallo P et al (1992) Pathologic explanation for hypoechoic halo seen on sonograms of malignant liver tumors: an in vitro correlative study. AJR Am J Roentgenol 159:1011–1016 CrossRefPubMed
22.
Zurück zum Zitat Tada T, Kumada T, Toyoda H et al (2016) Utility of combined gray-scale and perflubutane contrast-enhanced ultrasound for diagnosing early hepatocellular carcinomas: comparison of well differentiated and distinctly nodular types. Hepatol Res 46:1214–1225 CrossRefPubMed Tada T, Kumada T, Toyoda H et al (2016) Utility of combined gray-scale and perflubutane contrast-enhanced ultrasound for diagnosing early hepatocellular carcinomas: comparison of well differentiated and distinctly nodular types. Hepatol Res 46:1214–1225 CrossRefPubMed
23.
Zurück zum Zitat Martins-Filho SN, Paiva C, Azevedo RS, Alves VAF (2017) Histological grading of hepatocellular carcinoma-a systematic review of literature. Front Med (Lausanne) 4:193 CrossRefPubMed Martins-Filho SN, Paiva C, Azevedo RS, Alves VAF (2017) Histological grading of hepatocellular carcinoma-a systematic review of literature. Front Med (Lausanne) 4:193 CrossRefPubMed
24.
Zurück zum Zitat Kim SH, Lee WJ, Lim HK, Park CK (2009) SPIO-enhanced MRI findings of well-differentiated hepatocellular carcinomas: correlation with MDCT findings. Korean J Radiol 10:112–120 CrossRefPubMedPubMedCentral Kim SH, Lee WJ, Lim HK, Park CK (2009) SPIO-enhanced MRI findings of well-differentiated hepatocellular carcinomas: correlation with MDCT findings. Korean J Radiol 10:112–120 CrossRefPubMedPubMedCentral
25.
Zurück zum Zitat Mandai M, Koda M, Matono T et al (2011) Assessment of hepatocellular carcinoma by contrast-enhanced ultrasound with perfluorobutane microbubbles: comparison with dynamic CT. Br J Radiol 84:499–507 CrossRefPubMedPubMedCentral Mandai M, Koda M, Matono T et al (2011) Assessment of hepatocellular carcinoma by contrast-enhanced ultrasound with perfluorobutane microbubbles: comparison with dynamic CT. Br J Radiol 84:499–507 CrossRefPubMedPubMedCentral
26.
Zurück zum Zitat Kudo M, Hatanaka K, Inoue T, Maekawa K (2010) Depiction of portal supply in early hepatocellular carcinoma and dysplastic nodule: value of pure arterial ultrasound imaging in hepatocellular carcinoma. Oncology 78(Suppl 1):60–67 CrossRefPubMed Kudo M, Hatanaka K, Inoue T, Maekawa K (2010) Depiction of portal supply in early hepatocellular carcinoma and dysplastic nodule: value of pure arterial ultrasound imaging in hepatocellular carcinoma. Oncology 78(Suppl 1):60–67 CrossRefPubMed
27.
Zurück zum Zitat Takahashi M, Maruyama H, Ishibashi H, Yoshikawa M, Yokosuka O (2011) Contrast-enhanced ultrasound with perflubutane microbubble agent: evaluation of differentiation of hepatocellular carcinoma. AJR Am J Roentgenol 196:W123–W131 CrossRefPubMed Takahashi M, Maruyama H, Ishibashi H, Yoshikawa M, Yokosuka O (2011) Contrast-enhanced ultrasound with perflubutane microbubble agent: evaluation of differentiation of hepatocellular carcinoma. AJR Am J Roentgenol 196:W123–W131 CrossRefPubMed
28.
Zurück zum Zitat Inoue T, Kudo M, Maenishi O et al (2009) Value of liver parenchymal phase contrast-enhanced sonography to diagnose premalignant and borderline lesions and overt hepatocellular carcinoma. AJR Am J Roentgenol 192:698–705 CrossRefPubMed Inoue T, Kudo M, Maenishi O et al (2009) Value of liver parenchymal phase contrast-enhanced sonography to diagnose premalignant and borderline lesions and overt hepatocellular carcinoma. AJR Am J Roentgenol 192:698–705 CrossRefPubMed
29.
Zurück zum Zitat Min JH, Lim HK, Lim S et al (2014) Radiofrequency ablation of very-early-stage hepatocellular carcinoma inconspicuous on fusion imaging with B-mode US: value of fusion imaging with contrast-enhanced US. Clin Mol Hepatol 20:61–70 CrossRefPubMedPubMedCentral Min JH, Lim HK, Lim S et al (2014) Radiofrequency ablation of very-early-stage hepatocellular carcinoma inconspicuous on fusion imaging with B-mode US: value of fusion imaging with contrast-enhanced US. Clin Mol Hepatol 20:61–70 CrossRefPubMedPubMedCentral
30.
Zurück zum Zitat Shin J, Lee S, Bae H et al (2020) Contrast-enhanced ultrasound liver imaging reporting and data system for diagnosing hepatocellular carcinoma: a meta-analysis. Liver Int 40:2345–2352 CrossRefPubMed Shin J, Lee S, Bae H et al (2020) Contrast-enhanced ultrasound liver imaging reporting and data system for diagnosing hepatocellular carcinoma: a meta-analysis. Liver Int 40:2345–2352 CrossRefPubMed
31.
Zurück zum Zitat Kan M, Hiraoka A, Uehara T et al (2010) Evaluation of contrast-enhanced ultrasonography using perfluorobutane (Sonazoid((R))) in patients with small hepatocellular carcinoma: comparison with dynamic computed tomography. Oncol Lett 1:485–488 CrossRefPubMedPubMedCentral Kan M, Hiraoka A, Uehara T et al (2010) Evaluation of contrast-enhanced ultrasonography using perfluorobutane (Sonazoid((R))) in patients with small hepatocellular carcinoma: comparison with dynamic computed tomography. Oncol Lett 1:485–488 CrossRefPubMedPubMedCentral
32.
Zurück zum Zitat Hu J, Bhayana D, Burak KW, Wilson SR (2020) Resolution of indeterminate MRI with CEUS in patients at high risk for hepatocellular carcinoma. Abdom Radiol (NY) 45:123–133 CrossRefPubMed Hu J, Bhayana D, Burak KW, Wilson SR (2020) Resolution of indeterminate MRI with CEUS in patients at high risk for hepatocellular carcinoma. Abdom Radiol (NY) 45:123–133 CrossRefPubMed
33.
Zurück zum Zitat Wang DC, Jang HJ, Kim TK (2020) Characterization of indeterminate liver lesions on CT and MRI with contrast-enhanced ultrasound: what is the evidence? AJR Am J Roentgenol 214:1295–1304 CrossRefPubMed Wang DC, Jang HJ, Kim TK (2020) Characterization of indeterminate liver lesions on CT and MRI with contrast-enhanced ultrasound: what is the evidence? AJR Am J Roentgenol 214:1295–1304 CrossRefPubMed
34.
Zurück zum Zitat Ohama H, Imai Y, Nakashima O et al (2014) Images of Sonazoid-enhanced ultrasonography in multistep hepatocarcinogenesis: comparison with Gd-EOB-DTPA-enhanced MRI. J Gastroenterol 49:1081–1093 CrossRefPubMed Ohama H, Imai Y, Nakashima O et al (2014) Images of Sonazoid-enhanced ultrasonography in multistep hepatocarcinogenesis: comparison with Gd-EOB-DTPA-enhanced MRI. J Gastroenterol 49:1081–1093 CrossRefPubMed
35.
Zurück zum Zitat Korenaga K, Korenaga M, Furukawa M, Yamasaki T, Sakaida I (2009) Usefulness of Sonazoid contrast-enhanced ultrasonography for hepatocellular carcinoma: comparison with pathological diagnosis and superparamagnetic iron oxide magnetic resonance images. J Gastroenterol 44:733–741 CrossRefPubMed Korenaga K, Korenaga M, Furukawa M, Yamasaki T, Sakaida I (2009) Usefulness of Sonazoid contrast-enhanced ultrasonography for hepatocellular carcinoma: comparison with pathological diagnosis and superparamagnetic iron oxide magnetic resonance images. J Gastroenterol 44:733–741 CrossRefPubMed
36.
Zurück zum Zitat Board WCoTE (2019) Digestive system tumours, WHO Classification of Tumours, 5th ed. International Agency for Research on Cancer, Lyon, France, pp 229-239 Board WCoTE (2019) Digestive system tumours, WHO Classification of Tumours, 5th ed. International Agency for Research on Cancer, Lyon, France, pp 229-239
Metadaten
Titel
Perfluorobutane-enhanced ultrasonography with a Kupffer phase: improved diagnostic sensitivity for hepatocellular carcinoma
verfasst von
Jeong Ah Hwang
Woo Kyoung Jeong
Hyo-Jin Kang
Eun Sun Lee
Hyun Jeong Park
Jeong Min Lee
Publikationsdatum
16.06.2022
Verlag
Springer Berlin Heidelberg
Erschienen in
European Radiology / Ausgabe 12/2022
Print ISSN: 0938-7994
Elektronische ISSN: 1432-1084
DOI
https://doi.org/10.1007/s00330-022-08900-6

Weitere Artikel der Ausgabe 12/2022

European Radiology 12/2022 Zur Ausgabe

Update Radiologie

Update Radiologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert – ganz bequem per eMail.